Autor según el artículo: Brito-Zerón, P; Kostov, B; Fraile, G; Caravia-Durán, D; Maure, B; Rascón, FJ; Zamora, M; Casanovas, A; Lopez-Dupla, M; Ripoll, M; Pinilla, B; Fonseca, E; Akasbi, M; de la Red, G; Duarte-Millán, MA; Fanlo, P; Guisado-Vasco, P; Pérez-Alvarez, R; Chamorro, AJ; Morcillo, C; Jiménez-Heredia, I; Sánchez-Berná, I; López-Guillermo, A; Ramos-Casals, M
Departamento: Medicina i Cirurgia
Autor/es de la URV: López Dupla, Jesús Miguel
Palabras clave: 2016 revision Autoimmune-diseases Cancer Cohort Disease-activity Health-organization classification Lymphoma Malignancy Manifestations Mortality Non-hodgkins-lymphoma Predictors Sjögren syndrome
Resumen: Background: The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjogren syndrome (SjS).Methods: We had analyzed the development of cancer in 1300 consecutive patients fulfilling the 2002 SjS classification criteria. The baseline clinical and immunological characteristics and systemic activity (ESSDAI scores) were assessed at diagnosis as predictors of cancer using Cox proportional hazards regression analysis adjusted for age at diagnosis and gender. The sex-and age-specific standardized incidence ratios (SIR) of cancer were estimated from 2012 Spanish mortality data.Results: After a mean follow-up of 91 months, 127 (9.8%) patients developed 133 cancers. The most frequent type of cancer was B-cell lymphoma (including 27 MALT and 19 non-MALT B-cell lymphomas). Systemic activity at diagnosis of primary SjS correlated with the risk of hematological neoplasia and cryoglobulins with a high risk of either B-cell or non-B-cell lymphoma subtypes. Patients with cytopenias had a high risk of non-MALT B-cell and non-B-cell cancer, while those with low C3 levels had a high risk of MALT lymphomas and those with monoclonal gammopathy and low C4 levels had a high risk of non-MALT lymphomas. The estimated SIR for solid cancer was 1. 13 and 11.02 for hematological cancer. SIRs for specific cancers were 36.17 for multiple myeloma and immunoproliferative diseases, 19.41 for Hodgkin lymphoma, 6.04 for other non-Hodgkin lymphomas, 5.17 for thyroid cancer, 4.81 for cancers of the lip and oral cavity, and 2.53 for stomach cancer.Conclusions: One third of cancers developed by patients with primary SjS are B-cell lymphomas. The prognostic factors identified at SjS diagnosis differed according to the subtype of B-cell lymphoma developed. Primary SjS is also associated with the development of some non-hematological cancers (thyroid, oral cavity, and stomach).
Áreas temáticas: Biotecnología Cancer research Ciências biológicas ii Ciências biológicas iii Farmacia Hematology Medicina i Medicina ii Molecular biology Oncology
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: jesusmiguel.lopez@urv.cat
Identificador del autor: 0000-0002-9141-2523
Fecha de alta del registro: 2024-02-10
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-017-0464-5#Sec11
Referencia al articulo segun fuente origial: Journal Of Hematology & Oncology. 10
Referencia de l'ítem segons les normes APA: Brito-Zerón, P; Kostov, B; Fraile, G; Caravia-Durán, D; Maure, B; Rascón, FJ; Zamora, M; Casanovas, A; Lopez-Dupla, M; Ripoll, M; Pinilla, B; Fonseca, (2017). Characterization and risk estimate of cancer in patients with primary Sjogren syndrome. Journal Of Hematology & Oncology, 10(), -. DOI: 10.1186/s13045-017-0464-5
URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/
DOI del artículo: 10.1186/s13045-017-0464-5
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2017
Tipo de publicación: Journal Publications
Repositori URV